

Curriculum Vitae

**CV must be written in English*

Personal Information



Title (i.e. Prof., Dr., etc.)	Prof.
Name (First / Middle / Last)	Fernando Magro
Degree (i.e. MD, MSc, PhD, etc.)	PhD
Country	Portugal
Affiliation	<ol style="list-style-type: none"> Portuguese Inflammatory Bowel Disease Study Group (GEDII), Porto, Portugal CINTESIS@RISE, MEDCIDS, Faculty of Medicine, University of Porto, Porto, Portugal Department of Gastroenterology, Unidade Local de Saúde São João, Porto, Portugal Clinical Pharmacology Unit, Unidade Local de Saúde São João, Porto, Portugal Pharmacology and Toxicology Unit, Biomedicine Department, Faculty of Medicine, University of Porto, Porto, Portugal

Educational Background

2018 Aggregation in "Farmacologia e Toxicologia Experimentais e Clínicas"

2007 Doctorate degree in Pharmacology: Monoaminergic System in IBD and in a transmural model of colitis

1989 Bachelor degree in Medicine: Faculty of Medicine, University of Porto

Professional Experience

2023 – Present President-Elect of the European Crohn's and Colitis Organization (ECCO)

2020 – Present Member of the International Organization for the Study of Inflammatory Bowel Disease

2020 – Present Member of CINTESIS – Centro de Investigação em Tecnologias e Serviços de Saúde

2019 – Present Associate Editor, United European Gastroenterology Journal

2019 – 2023 Education Officer of the Governing Board, European Crohn's and Colitis Organization (ECCO)

2019 Honorary Member of Grupo de Estudo da Doença Inflamatória Intestinal

2018 – Present Director of the Clinical Pharmacology Unit, São João University Hospital Center

2017 – Present Board Member of the Portuguese IBD Study Group – GEDII

2017 Specialist of Clinical Pharmacology

2013 – 2019 Member of MEDinUP, Center for Drug Discovery and Innovative Medicines

2013 – 2016 ECCO Officer – ClinCom

2012 – Present Consultant of Gastroenterology, São João University Hospital Center

2012 – 2014 Member of Instituto de Patologia Molecular e Imunologia da Universidade do Porto (IBMC)

2012 – 2017 President of the Portuguese IBD Study Group (GEDII)

2011 Fellow of the European Board of Gastroenterology & Hepatology

2009 – 2013 ECCO Officer – GuiCom

2004 – 2007 President of the Portuguese IBD Study Group (GEDII)

2004 Founder of the Portuguese IBD Study Group (GEDII)

1998 – Present Gastroenterologist

Professional Organizations

1998 – Present Member of the Gastroenterology Department, São João University Hospital Center

Present Member of the Associate Laboratory of the University of Porto – RISE (Health Research Network)

International Organization for the Study of Inflammatory Bowel Disease (IOIBD)

American Gastroenterological Association (AGA)

Crohn's and Colitis Foundation of North America

European Crohn's and Colitis Organization (ECCO)

"Grupo de Estudos de Doença Inflamatória Intestinal" (GEDII)

Representative of Portugal in ECCO (2006-2007; 2012-2014)

"Sociedade Portuguesa de Coloproctologia"

"Sociedade Portuguesa de Endoscopia (SPED)"

Main Scientific Publications

"Sociedade Portuguesa de Gastrenterologia (SPG)"

"Sociedade Portuguesa de Farmacologia (SPF)"

Publications in indexed scientific journals

1. . W Colombel JF, Wu J, Kobayashi T, Zhu B, Paulissen J, Dhanabal A, Jairath V, Siegel C, Siegmund B, Redondo I, Moses R, **Magro F**. Mirikizumab impact on disease clearance in patients with moderately to severely active ulcerative colitis: analysis of a pre-specified LUCENT trial endpoint. J Crohns Colitis. 2025 Jul 12;jjaf124. doi: 10.1093/ecco-jcc/jjaf124. Epub ahead of print. PMID: 40651005.
2. Teixeira PV, **Magro F**, Estevinho MM. Advancing Precision in IBD Care: Innovations in Diagnosis, Monitoring, and Multidisciplinary Management. Biomedicines. 2025 Jun 10;13(6):1421. doi: 10.3390/biomedicines13061421. PMID: 40564140; PMCID: PMC12190162.
3. Fernandes SR, Rodrigues IC, Neves ADS, Saraiva S, Gonçalves AR, Santos PM, Valente A, Correia LA, Pinto HC, **Magro F**. Early Top-Down Treatment With Biologics Improves the Rates of Transmural

- Remission in Crohn's Disease-A Risk-Adjusted Propensity Score Matched Analysis. *Inflamm Bowel Dis.* 2025 Jun 25;izaf112. doi: 10.1093/ibd/izaf112. Epub ahead of print. PMID: 40556511.
- Honap S, Temido MJ, Shakweh E, Badrulhisham F, Shields N, Mehta S, McBride J, Uzzan M, Lukáš M, Fumery M, Nogami A, Kobayashi T, Nancey S, Neves JC, Mendes JM, Wegener BA, Bergereau E, Fernandes R, Kuzhianjal AJK, Vieujean S, Spencer A, Baillie S, Estevinho MM, Simão I, O'Neill C, Gututui M, Thompson E, Jama A, Chai N, Pavlidis P, D'Amico F, Limdi J, **Magro F**, Sebastian S, Digby-Bell J, Parkes GC, Din S, Hart A, Peyrin-Biroulet L; JAKne International Study Group. Janus Kinase (JAK) Inhibitor-Induced Acne in Inflammatory Bowel Disease: An International, Multicenter, Retrospective Cohort Study. *Clin Gastroenterol Hepatol.* 2025 Jun 11:S1542-3565(25)00465-3. doi: 10.1016/j.cgh.2025.04.031. Epub ahead of print. PMID: 40505791.
 - Shani U, State M, Mateescu RB, Davidoiu AM, Negreanu L, Silva I, **Magro F**, Lees CW, Plevris N, Roblin X, Castellet-Farrús S, Gonzalez Lama Y, Wang S, Abad C, Imperatore N, Lukas M, Vojtechova G, Ukashi O, Ben-Horin S, Nancey S, Savarino E, Stawczyk-Eder K, Eder P, Toskas A, Kamperidis N, Arebi N, Farkas B, Farkas K, Pipek B, Falt P, Karmiris K, Nikolaou P, Krznaric Z, Brinar M, Hoentjen F, van Lierop L, Barreiro-de Acosta M, Zaborowska M, Zagorowicz E, Pugliese D, Cuccia G, Truyens M, Kopylov U. The effectiveness of second- and third-line biologics in perianal Crohn's disease-a multicenter propensity score-matched study. *J Crohns Colitis.* 2025 Jun 4;19(6):jjaf099. doi: 10.1093/ecco-jcc/jjaf099. PMID: 40490896.
 - D'Amico F, Bencardino S, **Magro F**, Dignass A, Gutiérrez Casbas A, Verstockt B, Hart A, Armuzzi A, Peyrin-Biroulet L, Danese S. Positioning Guselkumab in The Treatment Algorithm of Patients with Crohn's Disease. *Biologics.* 2025 May 31;19:351-363. doi: 10.2147/BTT.S530354. PMID: 40470513; PMCID: PMC12136076.
 - Hanžel J, Solitano V, Vuyyuru SK, Panaccione R, Sands BE, Peyrin-Biroulet L, Danese S, D'Haens GR, Atreya R, Allez M, Bernstein CN, Bossuyt P, Bressler B, Bryant RV, Cohen BL, Colombel JF, D'Amico F, Dignass A, Dubinsky M, Fleshner P, Geary RB, Hanauer SB, Hart AL, Kayal M, Kucharzik T, Lakatos PL, Louis E, **Magro F**, Narula N, Leong RW, Panés J, Raine T, Ran Z, Regueiro MD, Reinisch W, Singh S, Steinhart AH, Travis S, Ungaro RC, van der Woude CJ, Yamamoto T, Ahuja V, Rubin DT, Dulai PS, Cornfield LJ, Hogan M, Sandborn WJ, Feagan BG, Jairath V, Ma C. An International Consensus on Appropriate Management of Corticosteroids in Clinical Trials in Inflammatory Bowel Disease. *Gastroenterology.* 2025 May 28:S0016-5085(25)00825-X. doi: 10.1053/j.gastro.2025.05.015. Epub ahead of print. PMID: 40446946.
 - Gordon M, Shaban N, Sinopoulou V, Vuyyuru S, Radford S, **Magro F**, Armuzzi A, Peyrin-Biroulet L, Jairath V, Moran G. Developing IBD Outcome Effect Size Thresholds to Inform Research, Guidelines, and Clinical Decisions. *Inflamm Bowel Dis.* 2025 May 13:izaf085. doi: 10.1093/ibd/izaf085. Epub ahead of print. PMID: 40357737.
 - Solitano V, Bernstein CN, Dotan I, Dignass A, Domilici R, Dubinsky MC, Geary RB, Hart A, Kaplan GG, Ma C, **Magro F**, Mak JWY, Ng SC, Panaccione R, Raja S, Rubin DT, Siegel CA, Jairath V, Peyrin-Biroulet L, Danese S. Shaping the future of inflammatory bowel disease: a global research agenda for better management and public health response. *Nat Rev Gastroenterol Hepatol.* 2025 Jun;22(6):438-452. doi: 10.1038/s41575-025-01063-x. Epub 2025 Apr 22. PMID: 40263433.
 - Alajmi A, Yuan Y, Solitano V, Rosenfeld DEC, Estevinho MM, **Magro F**, Nardone OM, Jairath V. 5-Aminosalicylates for non-surgical patients with active or quiescent Crohn's disease: an overview of systematic reviews (umbrella review). *J Crohns Colitis.* 2025 May 8;19(5):jjaf069. doi: 10.1093/ecco-jcc/jjaf069. PMID: 40255145.

11. Danese S, Peyrin-Biroulet L, Jairath V, D'Amico F, Adsul S, Agboton C, **Magro F**. Disease Clearance in Ulcerative Colitis: A Narrative Review. *United European Gastroenterol J*. 2025 Jul;13(6):902-910. doi: 10.1002/ueg2.12714. Epub 2025 Apr 16. PMID: 40237360; PMCID: PMC12269726.
12. Le Berre C, Jairath V, Panaccione R, Bourreille A, **Magro F**, Danese S, Peyrin-Biroulet L. Artificial Intelligence for Clinical Trial Facilitation, Lessons for Inflammatory Bowel Disease: A Scoping Review. *Clin Gastroenterol Hepatol*. 2025 Apr 10:S1542-3565(25)00278-2. doi: 10.1016/j.cgh.2025.01.030. Epub ahead of print. PMID: 40220847.
13. Jing F, Cao Y, Gong Q, Dan L, Zhu Y, **Magro F**, Fu T, Chen J, Wang X. Higher life's essential 8 score is associated with reduced risk of related surgery and all-cause mortality among 3,232 individuals with inflammatory bowel disease in a longitudinal cohort study. *Int J Surg*. 2025 Mar 12. doi: 10.1097/JS9.0000000000002335. Epub ahead of print. PMID: 40072359.
Ye S, Fu T, Tu Y, Wellens J, Chen X, Larsson SC, Sun J, Dan L, Wang X, Chen J, **Magro F**. Higher Dietary Glycemic Index, but not Glycemic Load, is Associated with Increased Risk of Ulcerative Colitis: A Prospective Cohort Study. *J Crohns Colitis*. 2025 Mar 6:jjaf036. doi: 10.1093/ecco-jcc/jjaf036. Epub ahead of print. PMID: 40048698.
14. Abushamma S, Yadete T, Nero N, Falloon K, Parker CE, Abreu MT, Ahuja V, Armuzzi A, Bemelman W, Bruining DH, Deepak P, Dignass A, Dotan I, Feagan BG, Fulmer C, Halfvarson J, Hart A, Holubar SD, Leong RW, Ma C, **Magro F**, McCurdy JD, Narula N, Panés J, Raine T, Regueiro M, Rogler G, Singh S, Sparrow MP, Spinelli A, Van Koughnett JA, Vuyyuru SK, Solitano V, Yuan Y, Jairath V, Rieder F. Definitions, Diagnosis and Management of Postoperative Recurrence in Crohn's Disease Patients with Permanent Ileostomy - A Systematic Review and Meta-Analysis. *J Crohns Colitis*. 2025 Mar 10:jjaf041. doi: 10.1093/ecco-jcc/jjaf041. Epub ahead of print. PMID: 40066499.
15. **Magro F**, Peyrin-Biroulet L, Sands BE, Danese S, Jairath V, Goetsch M, Bhattacharjee A, Wu J, Branquinho D, Modesto I, Feagan BG. Endoscopic, Histologic, and Composite Endpoints in Patients With Ulcerative Colitis Treated With Etrasimod. *Clin Gastroenterol Hepatol*. 2025 Feb;23(2):341-350.e6. doi: 10.1016/j.cgh.2024.07.010. Epub 2024 Jul 31. PMID: 39089519.
16. Solitano V, Estevinho MM, Ungaro F, **Magro F**, Danese S, Jairath V. TL1A Inhibition in Inflammatory Bowel Disease: A Pipeline Review. *BioDrugs*. 2025 Feb 5. doi: 10.1007/s40259-025-00706-4. Epub ahead of print. PMID: 39907869.
17. Temido MJ, Honap S, Danese S, Jairath V, **Magro F**, Portela F, Peyrin-Biroulet L. Nested Randomized Controlled Trials in Large Databases: An Opportunity for Inflammatory Bowel Disease? *J Crohns Colitis*. 2025 Feb 4;19(2):jjae136. doi: 10.1093/ecco-jcc/jjae136. PMID: 39208067.
18. Vieujean S, Jairath V, Peyrin-Biroulet L, Dubinsky M, Iacucci M, **Magro F**, Danese S. Understanding the therapeutic toolkit for inflammatory bowel disease. *Nat Rev Gastroenterol Hepatol*. 2025 Jan 31. doi: 10.1038/s41575-024-01035-7. Epub ahead of print. Erratum in: *Nat Rev Gastroenterol Hepatol*. 2025 Feb 10. doi: 10.1038/s41575-025-01047-x. PMID: 39891014.
19. Ukashi O, Amiot A, Laharie D, Menchén L, Gutiérrez A, Fernandes S, Pessarelli T, Correia F, Gonzalez-Muñoz C, López-Cardona J, Calabrese G, Ferreiro-Iglesias R, Tamir-Degabli N, Dussias NK, Mousa A, Oliveira R, Richard N, Veisman I, Sharif K, Ben-Horin S, Soutullo-Castiñeiras C, Dragoni G, Rotulo S, Favale A, Calmégane L, Bazin T, Elosua A, Lopes S, Felice C, Mauriz V, Rodrigues IC, Jougon J, Botto I, Tavares de Sousa H, Bertani L, Abadía PR, Bernardi A, Zabana Y, Serra-Ruiz X, Viola A, Barreiro-de Acosta M, Yanai H, Armuzzi A, **Magro F**, Kopylov U. Inter-Rater Disagreements in Applying the Montreal Classification for Crohn's Disease: The Five-Nations Survey Study. *United European Gastroenterol J*. 2025 Jan 18. doi: 10.1002/ueg2.12757. Epub ahead of print. PMID: 39825768.

20. Magalhaes D, Santiago M, Patita M, Arroja B, Lago P, Rosa I, Sousa HT, Ministro P, Mocanu I, Vieira A, Castela J, Moleiro J, Roseira J, Eugenia C, Sousa P, Portela F, Correia L, Dias S, Afonso J, Danese S, Peyrin-Biroulet L, Dias CC, **Magro F**; GEDII. Serum Neutrophil Biomarkers to Predict Crohn's Disease Progression and Infliximab Treatment Outcomes. *United European Gastroenterol J*. 2024 Dec 8. doi: 10.1002/ueg2.12712. Epub ahead of print. PMID: 39648597.
21. Estevinho MM, Roseira J, Teixeira PV, Dignass A, **Magro F**. Clinical Significance of histologic healing in IBD: Evidence from randomized controlled trials (RCT) and real world (RW) data. *Dig Liver Dis*. 2024 Dec 12:S1590-8658(24)01098-3. doi: 10.1016/j.dld.2024.11.009. Epub ahead of print. PMID: 39672772.
22. Rubin DT, Kubassova O, Weber CR, Adsul S, Freire M, Biedermann L, Koelzer VH, Bressler B, Xiong W, Niess JH, Matter MS, Kopylov U, Barshack I, Mayer C, **Magro F**, Carneiro F, Maharshak N, Greenberg A, Hart S, Dehmeshki J, Peyrin-Biroulet L. Deployment of an Artificial Intelligence Histology Tool to Aid Qualitative Assessment of Histopathology Using the Nancy Histopathology Index in Ulcerative Colitis. *Inflamm Bowel Dis*. 2024 Sep 16:izae204. doi: 10.1093/ibd/izae204. Epub ahead of print. PMID: 39284932.
23. Gomes SF, Valois A, Estevinho MM, Santiago M, **Magro F**. Association of Gut Microbiome and Dipeptidyl Peptidase 4 in Immune-Mediated Inflammatory Bowel Disease: A Rapid Literature Review. *Int J Mol Sci*. 2024 Nov 29;25(23):12852. doi: 10.3390/ijms252312852. PMID: 39684563; PMCID: PMC11641704.
24. Tavares de Sousa H, Ferreira M, Gullo I, Rocha AM, Pedro A, Leitão D, Oliveira C, Carneiro F, **Magro F**. Fibrosis-related Transcriptome Unveils a Distinctive Remodelling Matrix Pattern in Penetrating Ileal Crohn's Disease. *J Crohns Colitis*. 2024 Nov 4;18(11):1741-1752. doi: 10.1093/ecco-jcc/jjae064. PMID: 38700484.
25. Moreira PL, Dignass A, Estevinho MM, Portal F, Mendes J, Santiago M, Reinisch W, Sands BE, D'Haens G, Mantzaris GJ, Danese S, Peyrin-Biroulet L, Jairath V, Dotan I, **Magro F**; International Organization for the Study of Inflammatory Bowel Diseases (IOIBD). Assessment of outcomes in Crohn's disease: A systematic review of randomized clinical trials to inform a multiple outcome framework. *United European Gastroenterol J*. 2024 Nov;12(9):1280-1291. doi: 10.1002/ueg2.12679. Epub 2024 Oct 11. PMID: 39391955; PMCID: PMC11578837.
26. Parigi TL, Solitano V, Armuzzi A, Barreiro de Acosta M, Begun J, Ben-Horin S, Biedermann L, Colombel JF, Dignass A, Fumery M, Ghosh S, Kobayashi T, Louis E, **Magro F**, Panaccione R, Rausch A, Reinisch W, Selinger C, Jairath V, Danese S, Peyrin-Biroulet L. Defining mucosal healing in randomized controlled trials of inflammatory bowel disease: A systematic review and future perspective. *United European Gastroenterol J*. 2024 Nov;12(9):1266-1279. doi: 10.1002/ueg2.12671. Epub 2024 Oct 5. PMID: 39367753; PMCID: PMC11578850.
27. Estevinho MM, Sousa-Pinto B, Moreira PL, Solitano V, Mesquita P, Costa C, Peyrin-Biroulet L, Danese S, Jairath V, **Magro F**. Network Meta-Analysis: Histologic and Histo-Endoscopic Improvement and Remission With Advanced Therapy in Ulcerative Colitis. *Aliment Pharmacol Ther*. 2024 Nov;60(10):1276-1292. doi: 10.1111/apt.18315. Epub 2024 Oct 5. PMID: 39367678.
28. Abreu C, Monteiro C, Santiago M, Sarmento A, **Magro F**. The workup process of vaccination in IBD patients needs a change-Insights from a multinational survey. *Dig Liver Dis*. 2024 Nov;56(11):1958-1961. doi: 10.1016/j.dld.2024.07.031. Epub 2024 Aug 29. PMID: 39209595.
29. D'Amico F, **Magro F**, Dignass A, Al Awadhi S, Gutierrez Casbas A, Queiroz NSF, Rydzewska G, Duk Ye B, Ran Z, Hart A, Jairath V, Fiorino G, Peyrin-Biroulet L, Danese S. Practical management of mild-to-moderate ulcerative colitis: an international expert consensus. *Expert Rev Gastroenterol Hepatol*. 2024 Aug;18(8):421-430. doi: 10.1080/17474124.2024.2397650. Epub 2024 Sep 3. PMID: 39225555.

30. D'Amico F, Massimino L, Palmieri G, Dal Buono A, Gabbiadini R, Caron B, Moreira P, Silva I, Bosca-Watts M, Innocenti T, Dragoni G, Bezzio C, Zilli A, Furfaro F, Saibeni S, Chaparro M, García MJ, Michalopoulos G, Viazis N, Mantzaris GJ, Ellul P, Gisbert JP, **Magro F**, Peyrin-Biroulet L, Armuzzi A, Ungaro F, Danese S, Fiorino G, Allocca M. An international multicentre study of SwiTching from Intravenous to subcutaneous infliximab and vedolizumab in inflammatory bowel diseases: The TIME study. *Eur J Clin Invest.* 2024 Nov;54(11):e14283. doi: 10.1111/eci.14283. Epub 2024 Jul 9. PMID: 38979834.
31. Fernandes SR, Bernardo S, Saraiva S, Rita Gonçalves A, Moura Santos P, Valente A, Araújo Correia L, Cortez-Pinto H, **Magro F**. Proactive Infliximab Monitoring Improves the Rates of Transmural Remission in Crohn's Disease: A Propensity Score-Matched Analysis. *Inflamm Bowel Dis.* 2024 Nov 4;30(11):1974-1982. doi: 10.1093/ibd/izad272. PMID: 37982426.
32. Estevinho MM, Yuan Y, Rodríguez-Lago I, Sousa-Pimenta M, Dias CC, Barreiro-de Acosta M, Jairath V, **Magro F**. Efficacy and safety of probiotics in IBD: An overview of systematic reviews and updated meta-analysis of randomized controlled trials. *United European Gastroenterol J.* 2024 Sep;12(7):960-981. doi: 10.1002/ueg2.12636. Epub 2024 Aug 6. PMID: 39106167; PMCID: PMC11497663.
33. Borges-Carneiro F, Torre Souto M, Silva I, Leão Moreira P, Ferraz de Oliveira P, Lopes DJ, Figueira L, Reina-Couto M, Cunha-Miranda L, Ponces Bento D, **Magro F**. Clinical Trials in Portugal: Past and Future. Position Paper from the Colleges of Clinical Pharmacology and Pharmaceutical Medicine. *Acta Med Port.* 2024 Sep 2;37(9):585-588. doi: 10.20344/amp.21371. Epub 2024 Jul 31. PMID: 39082316.
34. Gisbert JP, Schreiber S, Siegel CA, **Magro F**, Jus A, Whichello C, Michaels-Igbokwe C, Heidenreich S, Oortwijn A, Vermeire S. Benefit-Risk Trade-offs and Patient Preferences for Therapy Selection in Ulcerative Colitis: a Multicountry Preference Study. *Inflamm Bowel Dis.* 2024 Aug 10;izae162. doi: 10.1093/ibd/izae162. Epub ahead of print. PMID: 39126434.
35. Ferreira-Duarte M, Oliveira LCG, Quintas C, Dias-Pereira P, Sousa T, **Magro F**, Casarini DE, Duarte-Araújo M, Morato M. Angiotensin-converting enzymes 1 and 2 in the feces: presence and catalytic activity in the rat 2,4,6-trinitrobenzene sulfonic acid-induced model of colitis. *J Gastroenterol Hepatol.* 2024 Sep;39(9):1885-1894. doi: 10.1111/jgh.16541. Epub 2024 Jul 5. PMID: 38967213.
36. Fernandes SR, Bernardo S, Saraiva S, Gonçalves AR, Moura Santos P, Valente A, Araújo Correia L, Cortez-Pinto H, **Magro F**. The degree of bowel remission predicts phenotype progression in Crohn's disease. *United European Gastroenterol J.* 2024 Sep;12(7):891-900. doi: 10.1002/ueg2.12581. Epub 2024 May 16. PMID: 38753521; PMCID: PMC11497657.
37. Sciberras M, Farrugia Y, Gordon H, Furfaro F, Allocca M, Torres J, Arebi N, Fiorino G, Iacucci M, Verstockt B, **Magro F**, Katsanos K, Busuttill J, De Giovanni K, Fenech VA, Chetcuti Zammit S, Ellul P. Accuracy of Information given by ChatGPT for Patients with Inflammatory Bowel Disease in Relation to ECCO Guidelines. *J Crohns Colitis.* 2024 Aug 14;18(8):1215-1221. doi: 10.1093/ecco-jcc/jjjae040. PMID: 38520394.
38. Olivera PA, Dignass A, Dubinsky MC, Peretto G, Kotze PG, Dotan I, Kobayashi T, Ghosh S, **Magro F**, Faria-Neto JR, Siegmund B, Danese S, Peyrin-Biroulet L. Preventing and managing cardiovascular events in patients with inflammatory bowel diseases treated with small-molecule drugs, an international Delphi consensus. *Dig Liver Dis.* 2024 Aug;56(8):1270-1280. doi: 10.1016/j.dld.2024.03.010. Epub 2024 Apr 6. PMID: 38584033.
39. D'Amico F, Gomollón F, Bamias G, **Magro F**, Targownik L, Leitner C, Heatta-Speicher T, Michelena N, Kolterer S, Laphorn J, Kauffman L, Dignass A; IBD PODCAST investigators. Proportion of inflammatory bowel diseases patients with suboptimal disease control in daily clinical practice-Real-world evidence from the inflammatory bowel diseases-podcast study. *United European Gastroenterol J.* 2024

Jul;12(6):705-716. doi: 10.1002/ueg2.12572. Epub 2024 May 11. PMID: 38733307; PMCID: PMC11328116.

40. Bethlehem L, Estevinho MM, Grinspan A, **Magro F**, Faith JJ, Colombel JF. Microbiota therapeutics for inflammatory bowel disease: the way forward. *Lancet Gastroenterol Hepatol*. 2024 May;9(5):476-486. doi: 10.1016/S2468-1253(23)00441-7. PMID: 38604201.
41. Allocca M, Catalano G, Savarino EV, Chaparro M, Levartovsky A, Michalopoulos G, Viazis N, Fousekis FS, Psistakis A, Noviello D, Nascimento CND, Caron B, Kitsou V, Bamias G, García MJ, Zacharopoulou E, Foteinogiannopoulou K, D'Amico F, Koutroubakis I, Ellul P, Tzouvala M, Peyrin-Biroulet L, Torres J, Caprioli F, Karmiris K, Theodoropoulou A, Katsanos KH, Christodoulou DK, Mantzaris GJ, Kopylov U, Gisbert JP, Danese S, **Magro F**, Carla F, Fiorino G. Comparison between tofacitinib and ustekinumab as a third-line therapy in refractory ulcerative colitis: A multicenter international study. *United European Gastroenterol J*. 2024 Feb 28. doi: 10.1002/ueg2.12492. Epub ahead of print. PMID: 38419274.
42. Fantini MC, Fiorino G, Colli A, Laharie D, Armuzzi A, Caprioli FA, Gisbert JP, Kirchgessner J, Macaluso FS, **Magro F**, Ghosh S; PRACTICE-IBD study group. Pragmatic trial design to compare real-world effectiveness of different treatments for inflammatory bowel diseases: the PRACTICE-IBD European consensus. *J Crohns Colitis*. 2024 Feb 17;jjae026. doi: 10.1093/ecco-jcc/jjae026. Epub ahead of print. PMID: 38367197.
43. **Magro F**, Estevinho MM, Valois A. Managing Ulcerative Colitis and Crohn's Disease: Should the Target Be Endoscopy, Histology, or Both? *J Can Assoc Gastroenterol*. 2023 Sep 23;7(1):46-58. doi: 10.1093/jcag/gwad034. PMID: 38314174; PMCID: PMC10836991.
44. **Magro F**, Fernandes S, Patita M, Arroja B, Lago P, Rosa I, de Sousa HT, Ministro P, Mocanu I, Vieira A, Castela J, Moleiro J, Roseira J, Cancela E, Sousa P, Portela F, Correia L, Moreira P, Dias S, Afonso J, Danese S, Peyrin-Biroulet L, Vucicevic KM, Santiago M. The influence of subclinical active inflammation on IFX pharmacokinetic modeling and disease progression assessment: findings from a prospective real-world study in inflammatory bowel disease patients. *J Crohns Colitis*. 2024 Jan 19;jjae014. doi: 10.1093/ecco-jcc/jjae014. Epub ahead of print. PMID: 38243908.
45. Pai RK, D'Haens G, Kobayashi T, Sands BE, Travis S, Jairath V, De Hertogh G, Park B, McGinnis K, Redondo I, Lipitz NG, Gibble TH, **Magro F**. Histologic assessments in ulcerative colitis: the evidence behind a new endpoint in clinical trials. *Expert Rev Gastroenterol Hepatol*. 2024 Jan-Feb;18(1-3):73-87. doi: 10.1080/17474124.2024.2326838. Epub 2024 Mar 21. PMID: 38509826.
46. Sousa P, **Magro F**. Author's Reply: "Immunomodulator combination versus mono therapy: Does combination therapy have an impact on infliximab therapy?". *Dig Liver Dis*. 2024 Mar;56(3):532-533. doi: 10.1016/j.dld.2023.12.006. Epub 2024 Jan 2. PMID: 38171940.

Book chapters

1. **Magro F** & Pita I. Patient Priorities. In: Sturm A., White L. (eds) *Inflammatory Bowel Disease Nursing Manual*. Springer, Cham (2019)
2. **Magro F** & António T. *Fibrostenotic Inflammatory Bowel Disease*, Springer (2018)
3. António Albino Teixeira & **Magro F**. Antiulcerosos. In *Terapêutica Medicamentosa e suas Bases Farmacológicas, Manual de Farmacologia e Farmacoterapia*, 488-498. 5ª Edição Porto Editora (eds) (2014).
4. António Albino Teixeira & **Magro F**. Modificadores da motilidade gastrointestinal. In *Terapêutica Medicamentosa e suas Bases Farmacológicas, Manual de Farmacologia e Farmacoterapia*, 499-503. 5ª Edição Porto Editora (eds) (2014).
5. António Albino Teixeira & **Magro F**. Modificadores da bile e da motilidade vesicular. In *Terapêutica Medicamentosa e suas Bases Farmacológicas, Manual de Farmacologia e Farmacoterapia*, 504-

AOCC 2026

IMKASID 2026

JUNE 25 (Thu.) - 27 (Sat.), 2026 | COEX, SEOUL, KOREA



507. 5ª Edição Porto Editora (eds) (2014).

6. **Magro F.** Imunofarmacologia. In *Terapêutica Medicamentosa e suas Bases Farmacológicas, Manual de Farmacologia e Farmacoterapia*, 804-811. 5ª Edição Porto Editora (eds) (2014).
7. Sarmiento A, Campos N, Appelberg R and **Magro F.** Defective macrophage function in Crohn's disease, *Macrophages: life cycle, functions and diseases*, 345-358. Nova Science Publishers (eds) (2012).
8. **Magro F** (2007). Inflammatory bowel disease high-risk groups. In *Intestinal inflammation and colorectal cancer*, 17-24. The Netherlands Springer and Falk Foundation (eds) (2007).
9. **Magro F.** Terapêutica na doença penetrante. In *Terapêutica Farmacológica na Doença Inflamatória do Intestino*, 180-187. Medisa, Portugal, GEDII (eds) (2007).
10. **Magro F** (2005). Angiotensin-converting enzyme (ACE) in Gut Inflammation. In *Proteases in gastrointestinal tissues*, 301-314. Uwe Lendeckel and Nigel Hooper (eds). The Netherlands, Springer (eds). (2005).
11. **Magro F**, F Tavela Veloso, F Carneiro Chaves. Fístulas na Doença de Crohn. In *Doença Inflamatória Intestinal*, 56-61. Lisbon. Permanyer Portugal (eds) (1996).